Johnson & Johnson (NYSE:JNJ) starts late-stage coronavirus vaccine clinical trial
Published
The phase 3 study of JNJ-78436735, which will enroll 60,000 participants, is underway.
Full ArticlePublished
The phase 3 study of JNJ-78436735, which will enroll 60,000 participants, is underway.
Full Article4:15 pm: Wall Street coasts to big gains The markets made strong gains at the opening bell and never let them go, led by robust..
Watch VideoA single-shot coronavirus vaccine has entered the final stages of testing.
Johnson & Johnson says it's..